ImmuCell Names Former Idexx Laboratories Exec As Its Next CEO

Dow Jones

Sep 30

By Emon Reiser

ImmuCell named Olivier te Boekhorst its next president and chief executive, effective Nov. 1. He will succeed the biotech's longtime leader, Michael Brigham, who has held the role since 2000.

Te Boekhorst is currently the operating partner at Archimed, a global investment firm that backs human and animal healthcare companies. He is also chair of SeqCenter, a DNA sequencing company where he was previously CEO. Te Boekhorst also held several leadership roles at Idexx Laboratories, where he's credited with leading merger and acquisition efforts to consolidate the pet healthcare company's livestock diagnostics segment.

Brigham will stay on as a special adviser to te Boekhorst for at least two months after he assumes the role at the animal health company, and then Brigham will continue to serve on the company's board of directors until its annual meeting. Brigham is subject to re-election by stockholders, the company said.

Immucell said in June it would embark on the CEO succession planning process to replace Brigham, who said at the time that he intended to retire in early 2026.

Write to Emon Reiser at emon.reiser@wsj.com

(END) Dow Jones Newswires

September 29, 2025 16:47 ET (20:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571368405"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571368405\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571368405?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 04:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571368405","market":"sg","top_or_hot":-1,"title":"ImmuCell Names Former Idexx Laboratories Exec As Its Next CEO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Emon Reiser \n</p>\n<p>\n  ImmuCell named Olivier te Boekhorst its next president and chief executive, effective Nov. 1. He will succeed the biotech's longtime leader, Michael Brigham, who has held the role since 2000. \n</p>\n<p>\n  Te Boekhorst is currently the operating partner at Archimed, a global investment firm that backs human and animal healthcare companies. He is also chair of SeqCenter, a DNA sequencing company where he was previously CEO. Te Boekhorst also held several leadership roles at Idexx Laboratories, where he's credited with leading merger and acquisition efforts to consolidate the pet healthcare company's livestock diagnostics segment. \n</p>\n<p>\n  Brigham will stay on as a special adviser to te Boekhorst for at least two months after he assumes the role at the animal health company, and then Brigham will continue to serve on the company's board of directors until its annual meeting. Brigham is subject to re-election by stockholders, the company said. \n</p>\n<p>\n  Immucell said in June it would embark on the CEO succession planning process to replace Brigham, who said at the time that he intended to retire in early 2026. \n</p>\n<p>\n  Write to Emon Reiser at emon.reiser@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2025 16:47 ET (20:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuCell Names Former Idexx Laboratories Exec As Its Next CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuCell Names Former Idexx Laboratories Exec As Its Next CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-30 04:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Emon Reiser \n</p>\n<p>\n  ImmuCell named Olivier te Boekhorst its next president and chief executive, effective Nov. 1. He will succeed the biotech's longtime leader, Michael Brigham, who has held the role since 2000. \n</p>\n<p>\n  Te Boekhorst is currently the operating partner at Archimed, a global investment firm that backs human and animal healthcare companies. He is also chair of SeqCenter, a DNA sequencing company where he was previously CEO. Te Boekhorst also held several leadership roles at Idexx Laboratories, where he's credited with leading merger and acquisition efforts to consolidate the pet healthcare company's livestock diagnostics segment. \n</p>\n<p>\n  Brigham will stay on as a special adviser to te Boekhorst for at least two months after he assumes the role at the animal health company, and then Brigham will continue to serve on the company's board of directors until its annual meeting. Brigham is subject to re-election by stockholders, the company said. \n</p>\n<p>\n  Immucell said in June it would embark on the CEO succession planning process to replace Brigham, who said at the time that he intended to retire in early 2026. \n</p>\n<p>\n  Write to Emon Reiser at emon.reiser@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2025 16:47 ET (20:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2571368405","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571368405","pubTimestamp":1759178820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmuCell named Olivier te Boekhorst its next president and chief executive, effective Nov. 1. He will succeed the biotech's longtime leader, Michael Brigham, who has held the role since 2000.Te Boekhorst is currently the operating partner at Archimed, a global investment firm that backs human and animal healthcare companies. He is also chair of SeqCenter, a DNA sequencing company where he was previously CEO. Te Boekhorst also held several leadership roles at Idexx Laboratories, where he's credited with leading merger and acquisition efforts to consolidate the pet healthcare company's livestock diagnostics segment.Brigham will stay on as a special adviser to te Boekhorst for at least two months after he assumes the role at the animal health company, and then Brigham will continue to serve on the company's board of directors until its annual meeting. Brigham is subject to re-election by stockholders, the company said.Immucell said in June it would embark on the CEO succession planning pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ICCC":"伊芙美尔医疗"},"translate_title":"ImmuCell任命前Idexx Laboratories高管为下一任首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCC":1.5},"content_text":"By Emon Reiser \n\n\n  ImmuCell named Olivier te Boekhorst its next president and chief executive, effective Nov. 1. He will succeed the biotech's longtime leader, Michael Brigham, who has held the role since 2000. \n\n\n  Te Boekhorst is currently the operating partner at Archimed, a global investment firm that backs human and animal healthcare companies. He is also chair of SeqCenter, a DNA sequencing company where he was previously CEO. Te Boekhorst also held several leadership roles at Idexx Laboratories, where he's credited with leading merger and acquisition efforts to consolidate the pet healthcare company's livestock diagnostics segment. \n\n\n  Brigham will stay on as a special adviser to te Boekhorst for at least two months after he assumes the role at the animal health company, and then Brigham will continue to serve on the company's board of directors until its annual meeting. Brigham is subject to re-election by stockholders, the company said. \n\n\n  Immucell said in June it would embark on the CEO succession planning process to replace Brigham, who said at the time that he intended to retire in early 2026. \n\n\n  Write to Emon Reiser at emon.reiser@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  September 29, 2025 16:47 ET (20:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}